Compare CPRX & WHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRX | WHD |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 2006 | 2018 |
| Metric | CPRX | WHD |
|---|---|---|
| Price | $31.28 | $58.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $35.00 | ★ $56.33 |
| AVG Volume (30 Days) | ★ 2.9M | 664.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | ★ 28.24 | 18.99 |
| EPS | ★ 0.50 | 0.19 |
| Revenue | $119,072,803.00 | ★ $1,079,051,000.00 |
| Revenue This Year | $9.20 | $43.92 |
| Revenue Next Year | $10.51 | $6.83 |
| P/E Ratio | ★ $62.58 | $305.79 |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $33.30 |
| 52 Week High | $32.56 | $64.30 |
| Indicator | CPRX | WHD |
|---|---|---|
| Relative Strength Index (RSI) | 72.86 | 52.66 |
| Support Level | $31.00 | $55.80 |
| Resistance Level | $31.33 | $58.53 |
| Average True Range (ATR) | 0.08 | 1.90 |
| MACD | -0.19 | -0.17 |
| Stochastic Oscillator | 81.94 | 38.94 |
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. It has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.